The biopharmaceutical firm reported a smaller-than-expected Q2 loss, driven by lower costs relative to estimates.
Minerva Neurosciences posted a Q2 GAAP loss per share of $0.14, beating expectations by $0.06. The narrower loss reflects cost management amid ongoing research activities.
Research and development expenses rose to $7.2 million for the quarter ended June 30, 2026, up from $1.3 million in the same period a year earlier. Cash reserves stood at $75.4 million as of June 30, 2026, down from $82.4 million at the end of 2025.
The company did not disclose immediate market reactions to the earnings report.